Back to search results

Observational Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)

This observational study aims to understand more about pulmonary recurrent respiratory papillomatosis (pRRP), a rare lung condition caused by human papillomavirus (HPV) types 6 and 11. Since pRRP is not well understood, researchers hope to learn about the genetic and immune system changes in these tumors, including those in the lungs. The study will look at tissue samples to see if HPV 6 or 11 is present in lung lesions and to identify different genetic changes in lung and voice box (laryngeal) lesions. This information could help develop new treatments. You may be able to join if you are 18 to 99 years old, have a history of HPV-associated recurrent respiratory papillomatosis, and have lung lesions. The study's current status is unclear.

Study design
This is an observational study collecting tissue samples from 100 participants. It is not testing a specific intervention or drug.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The study will measure outcomes related to HPV infection and genetic profiles in lung lesions at 24 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06412172

The Natural History and Biological Study of Pulmonary Recurrent Respiratory Papillomatosis (pRRP)

Recruiting
Not specifiedAges 18–99Observational
Massachusetts General Hospital
~100 participants
Updated 2025-08-12 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Participants with HPV 6 or 11 infection in the pulmonary lesions
Measured over 24 months
+1 more outcome measured

Conditions

Recurrent Respiratory Papillomatosis
Pulmonary Neoplasm

Explore related trials

Lung NeoplasmRecurrent Respiratory Papillomatosis

Where it's being run

1 sites across 1 states
Connecticut1

Study leadership

  • Sara Pai · PRINCIPAL_INVESTIGATOR · Yale University

Who to contact

Sara Pai, MD, PhD
[email protected]
203-785-5820
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

History of HPV-associated Recurrent Respiratory Papillomatosis
Has pulmonary lesions

Exclusion

None

What this trial measures

  • Number of Participants with HPV 6 or 11 infection in the pulmonary lesions24 months

    HPV 6 and 11 genotyping will be done via polymerase chain reaction

  • Number of Participants with different mutational profiles in the matched laryngeal and pulmonary lesions24 months

    Sequencing of the HPV genome in the matched laryngeal and pulmonary lesions will be performed.